InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,467.59
(
-0.03%
)
US TECH 100
19,177.20
(
0.01%
)
Dow Jones
39,160.08
(
0.12%
)
Brent Oil
84.78
(
0.70%
)
Bitcoin
61,070.88
(
-1.20%
)
Post# of 252370
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119921
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 161874

Saturday, 06/01/2013 3:57:35 PM

Saturday, June 01, 2013 3:57:35 PM

Post# of 252370
MRK is boldly testing Lambrolizumab* head-to-head vs BMY’s Yervoy in a phase-3 trial in advanced melanoma:

http://www.clinicaltrials.gov/ct2/show/NCT01866319

The primary endpoint is PFS, for which results are expected in Apr 2014. Unfortunately, the trial is open-label because the dosing intervals of the two drugs do not match.

*A/k/a MK-3475.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up